Award
National Institute of Arthritis and Musculoskeletal and Skin Diseases 1R01AR085258-01A1
Circulating cell free tumor DNA (ctDNA) in patients with immune checkpoint inhibitor associated inflammatory arthritis (ICI-IA): developing a biomarker to assess immunosuppressive drug safety
Recipient
Hospital for Special Surgery, New York, NY, United States
Award Amount
$267,423.00
Ceiling
$267,423.00
Awarded
September 08, 2025
Identifier
1R01AR085258-01A1
Research project funded by NIAMS to develop a biomarker using ctDNA to assess immunosuppressive drug safety in patients with immune checkpoint inhibitor associated inflammatory arthritis.
Description
This study measures circulating cell free tumor DNA in the plasma of patients with ICI-IA using a novel, highly sensitive assay to demonstrate its potential as a biomarker of cancer progression sensitive to immunosuppression effects, for use in future interventional studies.